<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04155047</url>
  </required_header>
  <id_info>
    <org_study_id>SUN101-402</org_study_id>
    <nct_id>NCT04155047</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Investigate if a Single Dose of an Approved Drug Product (Glycopyrrolate Inhalation Solution) Reduces Trapped Air in the Lungs of Participants With Chronic Obstructive Pulmonary Disease.</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, 2-Way Crossover Study of the Effect of a Single Dose of Glycopyrrolate Inhalation Solution (GIS) on Lung Hyperinflation in Subjects With Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunovion Respiratory Development Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunovion Respiratory Development Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical study to investigate if a single dose of an approved drug product (glycopyrrolate&#xD;
      Inhalation Solution) reduces trapped air in the lungs of participants with chronic&#xD;
      obstructive pulmonary disease. This study is accepting male and female participants over the&#xD;
      age of 40. The study will be conducted at one site located in the United States.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center, randomized, double-blind, placebo-controlled, single-dose, 2-way&#xD;
      crossover study in approximately 20 adult subjects ≥ 40 years of age with COPD. The study is&#xD;
      designed to evaluate the effect of a single dose of GIS on lung hyperinflation. The two study&#xD;
      treatments, both administered using the Magnair device.&#xD;
&#xD;
      The study will randomize 10 subjects per treatment sequence, for a total of 20 subjects. At&#xD;
      the Sponsor's discretion, additional subjects may be enrolled in an effort to achieve at&#xD;
      least 20 completers, with no more than 24 subjects randomize.&#xD;
&#xD;
      The study will consist of a Screening period, a randomized 2-way cross-over treatment period&#xD;
      during which subjects will receive two single-doses each separated by a 7-day washout period,&#xD;
      and a follow-up 7 (± 2) days after the last study drug dose.&#xD;
&#xD;
      This study is designed to test the hypothesis that in adults with COPD subjects as&#xD;
      characterized by the study inclusion/exclusion criteria, after 2 cross-over periods of&#xD;
      treatment, the primary null hypothesis for this study is that the mean change of RV from&#xD;
      baseline at 6 hours postdose for a single dose of GIS is equal to the mean change of RV from&#xD;
      baseline at 6 hours postdose for a single dose of placebo inhalation solution (PIS). The&#xD;
      alternative hypothesis is that these means are different.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 7, 2019</start_date>
  <completion_date type="Actual">March 31, 2020</completion_date>
  <primary_completion_date type="Actual">March 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>A Randomized, Double-blind, Placebo-controlled, 2-Way Crossover Study</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Residual Volume (RV) at 6 Hours Postdose</measure>
    <time_frame>6 hours post dose</time_frame>
    <description>Change from baseline in Residual Volume (Residual Volume is defined as the volume of gas that remains in lungs after maximal exhalation) at 6 hours postdose.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>Glycopyrrolate Inhalation Solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glycopyrrolate Inhalation Solution 25mcg administered by Magnair</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Inhalation Solution administered by Magair</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Glyocopyrrolate Inhalation Solution administered by Magnair</intervention_name>
    <description>glycopyrrolate Inhalation Solution 25mcg, single dose</description>
    <arm_group_label>Glycopyrrolate Inhalation Solution</arm_group_label>
    <other_name>LONHALA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo administered by Magnair</intervention_name>
    <description>Placebo Inhalation Solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is male or female and ≥ 40 years of age at Screening with a confirmed&#xD;
             diagnosis of COPD.&#xD;
&#xD;
        Subject must have the ability to comprehend the informed consent form and be willing to&#xD;
        provide informed consent.&#xD;
&#xD;
        Subject must possess an educational level and degree of understanding of English that&#xD;
        enables them to communicate suitably with the Investigator and the study coordinator.&#xD;
&#xD;
        Subject has a postbronchodilator (following inhalation of ipratropium bromide) FEV1 ≥ 30%&#xD;
        and &lt; 80% of predicted normal at Screening.&#xD;
&#xD;
        Subject has a postbronchodilator (following inhalation of ipratropium bromide) FEV1/FVC&#xD;
        ratio of &lt; 0.70 at Screening.&#xD;
&#xD;
        Subject has a RV ≥ 130% predicted value at Screening (prior to reversibility testing)&#xD;
        Subject is a current or former smoker with at least 10 pack-years of cigarette smoking&#xD;
        history at Screening.&#xD;
&#xD;
        Subject has a score of ≥ 2 on the Modified Medical Research Council Dyspnea Scale (mMRC) at&#xD;
        Screening.&#xD;
&#xD;
        Subject, if female of child bearing potential, must have a negative serum pregnancy test at&#xD;
        Screening. Females of childbearing potential must be instructed to and agree to avoid&#xD;
        pregnancy during the study and must use an acceptable method of birth control: a) an oral&#xD;
        contraceptive, an intrauterine device (IUD), implantable contraceptive, transdermal or&#xD;
        injectable contraceptive for at least 30 days prior to entering the study with continued&#xD;
        use throughout the study and for thirty days following participation; b) barrier method of&#xD;
        contraception, eg, condom and /or diaphragm with spermicide while participating in the&#xD;
        study; and/or c) abstinence. A follicle stimulating hormone (FSH) test will be used to&#xD;
        confirm menopause in postmenopausal females.&#xD;
&#xD;
        Subject is willing and able to attend all study visits and adhere to all study assessments&#xD;
        and procedures.&#xD;
&#xD;
          -  Exclusion Criteria:&#xD;
&#xD;
        Subject is female who is pregnant or lactating or are planning on becoming pregnant during&#xD;
        the study.&#xD;
&#xD;
        Subject has a history of asthma. Subject has a blood eosinophil count &gt; 5% of total white&#xD;
        blood cell count. Subject has life-threatening/unstable respiratory status, including upper&#xD;
        or lower respiratory tract infection, within the previous 30 days prior to Screening.&#xD;
&#xD;
        Recent history of COPD exacerbation requiring hospitalization or need for increased&#xD;
        treatments for COPD within 12 weeks prior to Screening.&#xD;
&#xD;
        Use of daily oxygen therapy &gt; 12 hours per day Subject is unable to perform&#xD;
        plethysmography. Subject is unable to use the Magnair Nebulizer System. Subject has history&#xD;
        of narrow angle glaucoma Subject has history of or clinically significant ongoing bladder&#xD;
        outflow obstruction or history of catheterization for relief of bladder outflow obstruction&#xD;
        within the previous 6 months prior to screening.&#xD;
&#xD;
        subject has history of long QT syndrome. subject has a QTcF &gt; 450 msec (males) or &gt; 470&#xD;
        msec (females) at Screening, unless discussed with and approved by the Medical Monitor.&#xD;
&#xD;
        Subject has a cardiac implanted device (internal defibrillator, pacemaker). Current severe&#xD;
        heart failure (New York Heart Association Class IV) [New York Heart Association, 1994].&#xD;
&#xD;
        Subject has history of malignancies within the past 5 years, with the exception of basal&#xD;
        cell carcinoma.&#xD;
&#xD;
        Subject has known comorbidities including unstable cardiac, pulmonary, or psychiatric&#xD;
        disease, or any other medical conditions that would, in the opinion of the Investigator,&#xD;
        preclude the subject from safely completing the required tests or the study, or is likely&#xD;
        to result in disease progression that would require withdrawal of the subject.&#xD;
&#xD;
        Subject has participated in another investigational drug study (within 30 days prior to&#xD;
        Screening).&#xD;
&#xD;
        Subjects who are study site staff members or relatives of study site staff members.&#xD;
&#xD;
        Subjects with a history of allergic reaction to glycopyrrolate, tiotropium, albuterol, or&#xD;
        any components of the study medications.&#xD;
&#xD;
        Subjects with a known allergy to hydrocolloid gel adhesive are excluded from wearing the&#xD;
        VitalPatch Biosensor.&#xD;
&#xD;
        -Continuation Criteria Subject has not had an exacerbation of COPD. Subject completes the&#xD;
        7-day washout period and continues to withhold restricted medications.&#xD;
&#xD;
        In the opinion of the Investigator, the subject has not had any change that would put the&#xD;
        safety of the subject at risk through participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Respiratory Medical Director</last_name>
    <role>Study Chair</role>
    <affiliation>Sunovion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Midwest Chest Consultants</name>
      <address>
        <city>Saint Charles</city>
        <state>Missouri</state>
        <zip>63301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 5, 2019</study_first_submitted>
  <study_first_submitted_qc>November 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2019</study_first_posted>
  <results_first_submitted>March 15, 2021</results_first_submitted>
  <results_first_submitted_qc>March 15, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 8, 2021</results_first_posted>
  <last_update_submitted>April 13, 2021</last_update_submitted>
  <last_update_submitted_qc>April 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Obstructive Pulmonary Disease (COPD)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study may be made available upon request via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>IPD will be made available upon request within 12 months of posting the study results on ct.gov.</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 7, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/47/NCT04155047/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 6, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/47/NCT04155047/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>There were 44 subjects enrolled in the study. There were 22 subjects that screen failed and did not participate in the study. There were 22 subjects that started the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Glycopyrrolate Inhalation Solution (GIS) First, Then Placebo Inhalation Solution (PIS)</title>
          <description>Treatment sequence AB: Single dose of GIS 25 mcg (Treatment A) to matching PIS (Treatment B)</description>
        </group>
        <group group_id="P2">
          <title>Placebo Inhalation Solution (PIS) First, Then Glycopyrrolate Inhalation Solution (GIS)</title>
          <description>Treatment sequence BA: Matching PIS (Treatment B) to single dose of GIS 25 mcg (Treatment A)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>COVID-19: SUBJECT REFUSED STUDY VISITS DUE TO COVID-19 THREAT</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Glycopyrrolate Inhalation Solution (GIS) First, Then Placebo Inhalation Solution (PIS)</title>
          <description>Treatment sequence AB: Single dose of GIS 25 mcg (Treatment A) to matching PIS (Treatment B)</description>
        </group>
        <group group_id="B2">
          <title>Placebo Inhalation Solution (PIS) First, Then Glycopyrrolate Inhalation Solution (GIS)</title>
          <description>Treatment sequence BA: Matching PIS (Treatment B) to single dose of GIS 25 mcg (Treatment A)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.4" spread="8.03"/>
                    <measurement group_id="B2" value="66.5" spread="8.12"/>
                    <measurement group_id="B3" value="65.9" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight (kg)</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96.69" spread="22.683"/>
                    <measurement group_id="B2" value="92.65" spread="23.808"/>
                    <measurement group_id="B3" value="94.67" spread="22.785"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height (cm)</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="166.4" spread="12.18"/>
                    <measurement group_id="B2" value="175.1" spread="8.94"/>
                    <measurement group_id="B3" value="170.8" spread="11.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI (kg/m^2)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.67" spread="6.131"/>
                    <measurement group_id="B2" value="30.14" spread="7.086"/>
                    <measurement group_id="B3" value="32.4" spread="6.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Residual Volume for GIS 25 mcg</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.132" spread="0.5631"/>
                    <measurement group_id="B2" value="3.696" spread="0.7570"/>
                    <measurement group_id="B3" value="3.414" spread="0.7123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Residual Volume for Placebo</title>
          <population>Among the 11 participants in treatment sequence AB, 2 participants received Treatment A (GIS 25mcg) in period 1 and did not continue into period 2. Therefore, there were only 9 participants with baseline measures for Treatment B (PIS).</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.174" spread="0.5669"/>
                    <measurement group_id="B2" value="3.592" spread="0.6915"/>
                    <measurement group_id="B3" value="3.404" spread="0.6575"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Residual Volume (RV) at 6 Hours Postdose</title>
        <description>Change from baseline in Residual Volume (Residual Volume is defined as the volume of gas that remains in lungs after maximal exhalation) at 6 hours postdose.</description>
        <time_frame>6 hours post dose</time_frame>
        <population>Efficacy Population : all subjects who were randomized, received at least one dose of study treatment, and have a baseline and at least one post-baseline RV measurement within the same period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo Inhalation Solution (PIS) administered by Magair</description>
          </group>
          <group group_id="O2">
            <title>GIS 25 mcg Single Dose</title>
            <description>Glycopyrrolate Inhalation Solution (GIS) 25 mcg administered by Magnair</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Residual Volume (RV) at 6 Hours Postdose</title>
          <description>Change from baseline in Residual Volume (Residual Volume is defined as the volume of gas that remains in lungs after maximal exhalation) at 6 hours postdose.</description>
          <population>Efficacy Population : all subjects who were randomized, received at least one dose of study treatment, and have a baseline and at least one post-baseline RV measurement within the same period.</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.004" spread="0.1392"/>
                    <measurement group_id="O2" value="-0.319" spread="0.1313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0987</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.323</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1861</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.711</ci_lower_limit>
            <ci_upper_limit>0.066</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo Inhalation Solution (PIS) administered by Magair</description>
        </group>
        <group group_id="E2">
          <title>GIS 25 mcg Single Dose</title>
          <description>Glycopyrrolate Inhalation Solution (GIS) 25 mcg administered by Magnair</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_vocab>MedDRA 22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In the event the Study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Respiratory Medical Director</name_or_title>
      <organization>Sunovion Respiratory Development Inc.</organization>
      <phone>1-866-503-6351</phone>
      <email>clinicaltrialdisclosure@sunovion.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

